Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04387916
PHASE1

A Study of KC1036 in Patients with Advanced Solid Tumors

Sponsor: Beijing Konruns Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety,tolerability, pharmacokinetics, and preliminary efficacy of KC1036 in participants with advanced recurrent or metastatic solid tumors. The trial will be divided into three parts: dose-escalation phase, dose-expansion phase, RP2D-extension phase.

Official title: A Phase I, Open-label, Dose Escalation Study Evaluating the Safety, Pharmacokinetics and Preliminary Efficacy of KC1036 in the Patients with Advanced Recurrent or Metastatic Solid Tumors

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

207

Start Date

2020-09-04

Completion Date

2025-12-31

Last Updated

2024-10-17

Healthy Volunteers

No

Interventions

DRUG

KC1036

Part 1: Dose-escalation phase , KC1036 10mg\~80mg, consists of 5 Cohorts. Part 2: Dose-expansion phase, consists of 3\~4 Cohorts based on part 1. Part 3:RP2D-extension phase, Recommended dose of KC1036 based on part 1and part 2.

Locations (3)

ChongQing University Cancer Hospital

Chongqing, Chongqing Municipality, China

The First Affiliated Hospital of Hainan Medical University

Haikou, Hainan, China

West China Hospital

Chengdu, Sichuan, China